Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Oct 22, 2013 (13 years ago)

Tacrolimus Capsules

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Cross Contamination with Other Products: findings of carryover of trace amounts of a previously manufactured product fluvastatin

Cause type: Cross-contamination

Traces of another drug - most often penicillin - got into the product from shared equipment or facilities. Even trace penicillin can trigger a severe allergic reaction in someone who was never meant to receive it. All cross-contamination recalls.

What was recalled

Tacrolimus Capsules, USP, 0.5 mg, 100 capsules/bottle, Rx only, Manufactured in India by Sandoz Private ltd. for Sandoz Inc., Princeton, NJ NDC 0781-2102-01

Affected NDC 0781-2102-01

Compare with the code on your package — it is the most precise check available.

Drug: Tacrolimus

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Tacrolimus
NDC 00781-2102
.5 mg/1 Capsule
Oral
Sandoz Inc. Rx
Recalling firm
Sandoz Incorporated
NDC code
0781-2102-01
Origin
CO, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-383-2014 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Tacrolimus recalls

See all
Class I · High risk

Prograf (tacrolimus)

Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Ongoing Failed specification Astellas Pharma US Inc. NDC 0469-0607-73 D-0211-2025
Class I · High risk

Astagraf XL

Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Ongoing Failed specification Astellas Pharma US Inc. NDC 0469-0647-73 D-0210-2025
Class II · Moderate risk

Tacrolimus Capsules

Presence of Foreign Tablets/Capsules: One 0.5 mg Tacrolimus capsule found in a bottle of 1 mg Tacrolimus capsules.

Terminated Particulate / foreign matter Dr. Reddy's Laboratories, Inc. NDC 55111-526-01 D-0219-2024
Class II · Moderate risk

Tacrolimus Capsules

Presence of Foreign Tablets/Capsules: Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labeled as Tacrolimus 0.5 mg capsules.

Ongoing Particulate / foreign matter Dr. Reddy's Laboratories, Inc. NDC 55111-525-01 D-0330-2023

Other recalls by Sandoz Incorporated

All 2013 recalls
Class II · Moderate risk

Nadolol Tablets

Failed dissolution specification: recalled due to an out of specification dissolution result of 40% (Specification: NLT 80%)

Terminated Dissolution failure Sandoz Incorporated NDC 0781-1182-10 D-0236-2017
Class III · Low risk

Fluoxetine Capsules USP

Labeling: Illegible Label: Sandoz Inc. is recalling of one lot of Fluoxetine Capsules due to an illegible logo on the capsule.

Terminated Labeling / mix-up Sandoz Incorporated NDC 0781-2822-01 D-0291-2015